TECH
Bio-TechneDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bio-Techne's premium tools and diagnostics exposure is showing pockets of strength: large pharma has grown double digits for six straight quarters, spatial biology is still expanding quickly, and management says funding activity may be turning more constructive. If that broadens, revenue can reaccelerate and the stock could move toward the sell-side median target.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Emerging biotech demand is still lagging, and management said broad-based demand has not yet materialized.
Momentum
12
Value
61
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $49.00 · Bull $66.00 · Bear $36.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $75.25
Why
Momentum12 · Δ7d +2.9
Value61 · Δ7d +0.0
Sentiment49 · Δ7d -2.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
12
34% active weight
Current posture
7d trendImproving
Δ7d
+2.9
Δ21d
+4.7
Value
61
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
49
33% active weight
Current posture
7d trendSoftening
Δ7d
-2.4
Δ21d
-39.6
Why this grade
Composite grade D. Momentum 12.2 / Value 61.5 / Sentiment 49.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$7.95B
Beta
1.48
Shares Out
155.81M
P/E (TTM)
130.6
P/S (TTM)
8.07
P/FCF (TTM)
56.47
Rev YoY
-1.0%
EPS YoY
+17.1%
Gross Margin
+66.8%
Op Margin
+9.0%
Net Debt
$183.81M
Current Ratio
4.22
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology